Employees: 905
Size Standard Engineering Technology (SETL.NS) is an India Health Care company (Medical Specialties) with a market value of $783M, the 686th largest of 1,066 India companies the cockpit tracks. Shares closed at ₹366.45 on 18 Nov 2026.
Performance Over six months the shares gained 167.5%, against -16.3% for the median peer and +3.8% for the India market (cap-weighted) — highest of 21 in its peer set.
Growth Revenue grew 45.3% over the last twelve months (peer median +10.2%); the operating margin is 13.8% (peer median 11.4%).
Valuation It trades at 7.7× enterprise value to sales against a peer median of 3.1× (3rd most expensive of 21).
Capital Return on invested capital runs 10.4 points below its cost of capital (20.0% WACC).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₹9.63B | ₹7.74B | ₹6.14B | ₹5.44B | ₹4.98B |
| Revenue growth | — | +26% | +13% | +9% | — |
| Gross profit | ₹2.47B | ₹1.49B | ₹1.27B | ₹1.08B | ₹968M |
| EBITDA | ₹1.52B | ₹1.21B | ₹1.09B | ₹963M | ₹861M |
| Net income | ₹917M | ₹800M | ₹643M | ₹584M | ₹534M |
| Free cash flow | n/a | -₹54.7M | -₹265M | -₹1.07B | -₹340M |
| Capital expenditure | n/a | ₹615M | ₹278M | ₹336M | ₹294M |
| Total debt | ₹1.83B | ₹807M | ₹658M | ₹1.27B | ₹780M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SETL.NS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +6.5% | -6.7% | 4th highest of 21 |
| 6-month return | +167.5% | -16.3% | highest of 21 |
| Distance from 52-week high | -21.7% | -39.8% | 8th highest of 21 |
| Revenue growth (TTM) | +45.3% | +10.2% | highest of 21 |
| Operating margin | 13.8% | 11.4% | 8th highest of 21 |
| EV / Sales | 7.7× | 3.1× | 3rd most expensive of 21 |
| ROIC minus cost of capital | -10.4 pp | -1.9 pp | 6th lowest of 21 |
| EV / EBITDA | 48.9× | 13.1× | most expensive of 9 |
| Net debt / EBITDA | 0.1× | 0.3× | 5th least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | 7.7× | n/a | n/a |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | 4.3× | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 3.6× | 21.3% | +13.2% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | 2.6× | n/a | n/a |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 3.2× | 9.6% | +15.5% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 1.2× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 3.6× | 3.8% | +105.8% |
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 1.2× | -6.7% | -15.9% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 2.3× | 7.9% | -10.2% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 3.0× | 20.0% | +21.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 3.6× | 2.7% | +20.9% |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 7.8× | 27.9% | +9.9% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | 9.6× | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | 6.8× | 35.6% | +17.1% |
| Allmed Medical Products 002950.SZ | China | $747M | -32% | +14% | 8% | 1.5× | n/a | n/a |
| Jiang Xi Sanxin Medtec 300453.SZ | China | $744M | -3% | +12% | 18% | 2.8× | -1.9% | +11.8% |
| Shanghai Runda Medical Technology 603108.SS | China | $744M | -36% | -12% | -2% | 1.7× | 20.3% | -0.2% |
| InMode INMD | United States | $741M | -8% | +2% | 18% | 0.6× | -10.8% | +12.4% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | 3.4× | n/a | n/a |
| Beijing Aerospace Changfeng 600855.SS | China | $738M | -44% | -10% | -19% | 4.5× | n/a | n/a |
| BMC Medical 301367.SZ | China | $737M | -17% | +37% | 17% | 1.8× | -1.5% | +15.6% |